Status: Recruiting
A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1
The purpose of this study is to find out whether the study drug mogamulizumab is effective in preventing the development of adult T-cell leukemia/lymphoma (ATL) in people who are at higher risk for this type of cancer because they are infected with the HTLV-1 virus and because of changes seen in some of their immune system cells called T-cells.
Participants needed: 134
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Memorial Sloan Kettering Cancer CenterUpdated: Mar 5, 2026Locations: 7
Eligibility criteria
Age ≥18 years when informed consent is obtained [+16]
Neutrophil count: ≤1000/mm3, unless patient has diagnosis of ethnic neutropenia [+19]